Cellid Co. Ltd (299660.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · South Korea · ISIN KR7299660001

Price
1,888.00 KRW
Market cap
55.70 bn KRW
P/E (2025)
–
P/S (2025)
6.30
Dividend yield
0.00 %
Net margin
-136.50 %
Return on equity (ROE)
-16.26 %
Return on assets (ROA)
-10.89 %

Cellid Co. Ltd financials

Fiscal year20242025
Revenue4.17 bn KRW8.84 bn KRW
Gross profit705.01 m KRW1.58 bn KRW
Operating income-11.79 bn KRW-11.34 bn KRW
EBIT-11.79 bn KRW-11.93 bn KRW
Net income-12.26 bn KRW-12.07 bn KRW
Diluted EPS – continuing operations-515.96 KRW-409.08 KRW

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Cellid Co. Ltd

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.